Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsGene Therapeutics & RNAi

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1285864

Cover Image

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1285864

Viral Vector Production Market (Vector Type: Adenovirus, Adeno-associated Virus, Retroviruses, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

PUBLISHED:
PAGES: 256 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5795
PDF (Multi-user License)
USD 8795
PDF (Corporate License)
USD 11795

Add to Cart

Description

Table of Contents

List of Tables

Viral Vector Production Market - Scope of Report

TMR's report on the global Viral Vector Production Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Viral Vector Production Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Viral Vector Production Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Viral Vector Production market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Viral Vector Production market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Viral Vector Production market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Viral Vector Production market.

The report delves into the competitive landscape of the global Viral Vector Production market. Key players operating in the global Viral Vector Production Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Viral Vector Production Market profiled in this report.

Key Questions Answered in Global Viral Vector Production Market Report:

  • What is the sales/revenue generated by Viral Vector Production across all regions during the forecast period?
  • What are the opportunities in the global Viral Vector Production market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Viral Vector Production Market - Research Objectives and Research Approach

The comprehensive report on the global Viral Vector Production Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Viral Vector Production Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Viral Vector Production market.

Show more
Product Code: TMRGL85250

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Viral Vector Production Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Vector Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Viral Vector Production Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Evolution of Gene Therapy
  • 5.2. Pipeline Analysis
  • 5.3. Regulatory Scenario, by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Viral Vector Production Market Analysis and Forecast, by Vector Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Vector Type, 2017-2031
    • 6.3.1. Adenovirus
    • 6.3.2. Adeno-associated virus
    • 6.3.3. Retroviruses
    • 6.3.4. Others (baculoviruses, lentivirus, etc.)
  • 6.4. Market Attractiveness Analysis, by Vector Type

7. Global Viral Vector Production Market Analysis and Forecast, by Disease

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Disease, 2017-2031
    • 7.3.1. Genetic Diseases
    • 7.3.2. Infectious Diseases
    • 7.3.3. Cancer
    • 7.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
  • 7.4. Market Attractiveness Analysis, by Disease

8. Global Viral Vector Production Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Gene Therapy
    • 8.3.2. Vaccinology
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Viral Vector Production Market Analysis and Forecast, by Mode

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Mode, 2017-2031
    • 9.3.1. Transient Transfection
    • 9.3.2. Stable Producer Cell Lines
  • 9.4. Market Attractiveness Analysis, by Mode

10. Global Viral Vector Production Market Analysis and Forecast, by End-user

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast, by End-user, 2017-2031
    • 10.3.1. Pharmaceutical & Biotechnology Companies
    • 10.3.2. Academic & Research Institutes
    • 10.3.3. CROs & CDMOs
  • 10.4. Market Attractiveness Analysis, by End-user

11. Global Viral Vector Production Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Viral Vector Production Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Vector Type, 2017-2031
    • 12.2.1. Adenovirus
    • 12.2.2. Adeno-associated virus
    • 12.2.3. Retroviruses
    • 12.2.4. Others (baculoviruses, lentivirus, etc.)
  • 12.3. Market Value Forecast, by Disease, 2017-2031
    • 12.3.1. Genetic Diseases
    • 12.3.2. Infectious Diseases
    • 12.3.3. Cancer
    • 12.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
  • 12.4. Market Value Forecast, by Application, 2017-2031
    • 12.4.1. Gene Therapy
    • 12.4.2. Vaccinology
  • 12.5. Market Value Forecast, by Mode, 2017-2031
    • 12.5.1. Transient Transfection
    • 12.5.2. Stable Producer Cell Lines
  • 12.6. Market Value Forecast, by End-user, 2017-2031
    • 12.6.1. Pharmaceutical & Biotechnology Companies
    • 12.6.2. Academic & Research Institutes
    • 12.6.3. CROs & CDMOs
  • 12.7. Market Value Forecast, by Country, 2017-2031
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Vector Type
    • 12.8.2. By Disease
    • 12.8.3. By Application
    • 12.8.4. By Mode
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Viral Vector Production Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Vector Type, 2017-2031
    • 13.2.1. Adenovirus
    • 13.2.2. Adeno-associated virus
    • 13.2.3. Retroviruses
    • 13.2.4. Others (baculoviruses, lentivirus, etc.)
  • 13.3. Market Value Forecast, by Disease, 2017-2031
    • 13.3.1. Genetic Diseases
    • 13.3.2. Infectious Diseases
    • 13.3.3. Cancer
    • 13.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
  • 13.4. Market Value Forecast, by Application, 2017-2031
    • 13.4.1. Gene Therapy
    • 13.4.2. Vaccinology
  • 13.5. Market Value Forecast, by Mode, 2017-2031
    • 13.5.1. Transient Transfection
    • 13.5.2. Stable Producer Cell Lines
  • 13.6. Market Value Forecast, by End-user, 2017-2031
    • 13.6.1. Pharmaceutical & Biotechnology Companies
    • 13.6.2. Academic & Research Institutes
    • 13.6.3. CROs & CDMOs
  • 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.7.1. Germany
    • 13.7.2. U.K.
    • 13.7.3. France
    • 13.7.4. Spain
    • 13.7.5. Italy
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Vector Type
    • 13.8.2. By Disease
    • 13.8.3. By Application
    • 13.8.4. By Mode
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Viral Vector Production Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Vector Type, 2017-2031
    • 14.2.1. Adenovirus
    • 14.2.2. Adeno-associated virus
    • 14.2.3. Retroviruses
    • 14.2.4. Others (baculoviruses, lentivirus, etc.)
  • 14.3. Market Value Forecast, by Diseases, 2017-2031
    • 14.3.1. Genetic Diseases
    • 14.3.2. Infectious Diseases
    • 14.3.3. Cancer
    • 14.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
  • 14.4. Market Value Forecast, by Application, 2017-2031
    • 14.4.1. Gene Therapy
    • 14.4.2. Vaccinology
  • 14.5. Market Value Forecast, by Mode, 2017-2031
    • 14.5.1. Transient Transfection
    • 14.5.2. Stable Producer Cell Lines
  • 14.6. Market Value Forecast, by End-user, 2017-2031
    • 14.6.1. Pharmaceutical & Biotechnology Companies
    • 14.6.2. Academic & Research Institutes
    • 14.6.3. CROs & CDMOs
  • 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Vector Type
    • 14.8.2. By Disease
    • 14.8.3. By Application
    • 14.8.4. By Mode
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Viral Vector Production Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Vector Type, 2017-2031
    • 15.2.1. Adenovirus
    • 15.2.2. Adeno-associated virus
    • 15.2.3. Retroviruses
    • 15.2.4. Others (baculoviruses, lentivirus, etc.)
  • 15.3. Market Value Forecast, by Disease, 2017-2031
    • 15.3.1. Genetic Diseases
    • 15.3.2. Infectious Diseases
    • 15.3.3. Cancer
    • 15.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
  • 15.4. Market Value Forecast, by Application, 2017-2031
    • 15.4.1. Gene Therapy
    • 15.4.2. Vaccinology
  • 15.5. Market Value Forecast, by Mode, 2017-2031
    • 15.5.1. Transient Transfection
    • 15.5.2. Stable Producer Cell Lines
  • 15.6. Market Value Forecast, by End-user, 2017-2031
    • 15.6.1. Pharmaceutical & Biotechnology Companies
    • 15.6.2. Academic & Research Institutes
    • 15.6.3. CROs & CDMOs
  • 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Vector Type
    • 15.8.2. By Disease
    • 15.8.3. By Application
    • 15.8.4. By Mode
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Viral Vector Production Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Vector Type, 2017-2031
    • 16.2.1. Adenovirus
    • 16.2.2. Adeno-associated virus
    • 16.2.3. Retroviruses
    • 16.2.4. Others (baculoviruses, lentivirus, etc.)
  • 16.3. Market Value Forecast, by Disease, 2017-2031
    • 16.3.1. Genetic Diseases
    • 16.3.2. Infectious Diseases
    • 16.3.3. Cancer
    • 16.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
  • 16.4. Market Value Forecast, by Application, 2017-2031
    • 16.4.1. Gene Therapy
    • 16.4.2. Vaccinology
  • 16.5. Market Value Forecast, by Mode, 2017-2031
    • 16.5.1. Transient Transfection
    • 16.5.2. Stable Producer Cell Lines
  • 16.6. Market Value Forecast, by End-user, 2017-2031
    • 16.6.1. Pharmaceutical & Biotechnology Companies
    • 16.6.2. Academic & Research Institutes
    • 16.6.3. CROs & CDMOs
  • 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Vector Type
    • 16.8.2. By Disease
    • 16.8.3. By Application
    • 16.8.4. By Mode
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2. Market Share Analysis By Company (2021)
  • 17.3. Company Profiles
    • 17.3.1. Pfizer, Inc.
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Test Type Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. Johnson & Johnson
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Test Type Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. AstraZeneca
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Test Type Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Sanofi
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Test Type Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. Novartis AG
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Test Type Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Test Type Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. GlaxoSmithKline plc
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Test Type Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Merck KGaA (Merck & Co., Inc.)
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Test Type Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Lonza
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Test Type Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. FUJIFILM Diosynth Biotechnologies Inc.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Test Type Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
    • 17.3.11. Oxford Biomedica plc
      • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.11.2. Test Type Portfolio
      • 17.3.11.3. Financial Overview
      • 17.3.11.4. SWOT Analysis
      • 17.3.11.5. Strategic Overview
    • 17.3.12. Amgen Inc.
      • 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.12.2. Test Type Portfolio
      • 17.3.12.3. Financial Overview
      • 17.3.12.4. SWOT Analysis
      • 17.3.12.5. Strategic Overview
    • 17.3.13. Ferring B.V.
      • 17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.13.2. Test Type Portfolio
      • 17.3.13.3. Financial Overview
      • 17.3.13.4. SWOT Analysis
      • 17.3.13.5. Strategic Overview
    • 17.3.14. uniQure N.V.
      • 17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.14.2. Test Type Portfolio
      • 17.3.14.3. Financial Overview
      • 17.3.14.4. SWOT Analysis
      • 17.3.14.5. Strategic Overview
    • 17.3.15. bluebird bio, Inc.
      • 17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.15.2. Test Type Portfolio
      • 17.3.15.3. Financial Overview
      • 17.3.15.4. SWOT Analysis
      • 17.3.15.5. Strategic Overview
    • 17.3.16. GenScript ProBio
      • 17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.16.2. Test Type Portfolio
      • 17.3.16.3. Financial Overview
      • 17.3.16.4. SWOT Analysis
      • 17.3.16.5. Strategic Overview
    • 17.3.17. Thermo Fisher Scientific, Inc.
      • 17.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.17.2. Test Type Portfolio
      • 17.3.17.3. Financial Overview
      • 17.3.17.4. SWOT Analysis
      • 17.3.17.5. Strategic Overview
    • 17.3.18. Gamaleya Research Institute
      • 17.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.18.2. Test Type Portfolio
      • 17.3.18.3. Financial Overview
      • 17.3.18.4. SWOT Analysis
      • 17.3.18.5. Strategic Overview
Show more
Product Code: TMRGL85250

List of Tables

  • Table 01: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
  • Table 02: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
  • Table 03: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
  • Table 04: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
  • Table 05: Global Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
  • Table 06: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Region, 2017-2032
  • Table 07: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Country, 2017-2032
  • Table 08: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
  • Table 09: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
  • Table 10: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
  • Table 11: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
  • Table 12: North America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
  • Table 13: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
  • Table 14: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
  • Table 15: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
  • Table 16: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
  • Table 17: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
  • Table 18: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
  • Table 19: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
  • Table 20: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
  • Table 21: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
  • Table 22: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
  • Table 23: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
  • Table 24: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
  • Table 25: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
  • Table 26: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
  • Table 27: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
  • Table 28: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
  • Table 29: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
  • Table 30: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032
  • Table 31: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032
  • Table 32: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032
  • Table 33: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032
  • Table 34: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032
  • Table 35: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032
  • Table 36: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

List of Figures

  • Figure 01: Global Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032
  • Figure 02: Global Viral Vector Production Market Value Share, by Vector Type, 2022
  • Figure 03: Global Viral Vector Production Market Value Share, by Disease, 2022
  • Figure 04: Global Viral Vector Production Market Value Share, by Application, 2022
  • Figure 05: Global Viral Vector Production Market Value Share, by Mode, 2022
  • Figure 06: Global Viral Vector Production Market Value Share, by End-user, 2022
  • Figure 07: Global Viral Vector Production Market Value Share, by Region, 2022
  • Figure 08: Global Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032
  • Figure 09: Global Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2031
  • Figure 10: Global Viral Vector Production Market (US$ Mn), by Adenovirus, 2017-2032
  • Figure 11 Global Viral Vector Production Market (US$ Mn), by Adeno-associated Virus, 2017-2031
  • Figure 12: Global Viral Vector Production Market (US$ Mn), by Retroviruses, 2017-2032
  • Figure 13: Global Viral Vector Production Market (US$ Mn), by Others, 2017-2032
  • Figure 14: Global Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032
  • Figure 15: Global Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2031
  • Figure 16: Global Viral Vector Production Market (US$ Mn), by Genetic Diseases, 2017-2032
  • Figure 17: Global Viral Vector Production Market (US$ Mn), by Infectious Diseases, 2017-2032
  • Figure 18: Global Viral Vector Production Market (US$ Mn), by Cancer, 2017-2032
  • Figure 19: Global Viral Vector Production Market (US$ Mn), by Others, 2017-2032
  • Figure 20: Global Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032
  • Figure 21: Global Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032
  • Figure 22: Global Viral Vector Production Market (US$ Mn), by Gene therapy, 2017-2032
  • Figure 23: Global Viral Vector Production Market (US$ Mn), by Vaccinology, 2017-2032
  • Figure 24: Global Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032
  • Figure 25: Global Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032
  • Figure 26: Global Viral Vector Production Market (US$ Mn), by Transient Transfection, 2017-2032
  • Figure 27: Global Viral Vector Production Market (US$ Mn), by Stable Producer Cell Lines, 2017-2032
  • Figure 28: Global Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032
  • Figure 29: Global Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 30: Global Viral Vector Production Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2032
  • Figure 31: Global Viral Vector Production Market (US$ Mn), by Academic & Research Institutes, 2017-2032
  • Figure 32: Global Viral Vector Production Market Value Share Analysis, by Region, 2022 and 2032
  • Figure 33: Global Viral Vector Production Market Attractiveness Analysis, by Region, 2023-2032
  • Figure 34: North America Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032
  • Figure 35: North America Viral Vector Production Market Value Share Analysis, by Country, 2022 and 2032
  • Figure 36: North America Viral Vector Production Market Attractiveness Analysis, by Country, 2023-2032
  • Figure 37: North America Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032
  • Figure 38: North America Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032
  • Figure 39: North America Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032
  • Figure 40: North America Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032
  • Figure 41: North America Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032
  • Figure 42: North America Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032
  • Figure 43: North America Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032
  • Figure 44: North America Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032
  • Figure 45: North America Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032
  • Figure 46: North America Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 47: Europe Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032
  • Figure 48: Europe Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
  • Figure 49: Europe Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032
  • Figure 50: Europe Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032
  • Figure 51: Europe Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032
  • Figure 52: Europe Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032
  • Figure 53: Europe Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032
  • Figure 54: Europe Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032
  • Figure 55: Europe Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032
  • Figure 56: Europe Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032
  • Figure 57: Europe Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032
  • Figure 58: Europe Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032
  • Figure 59: Europe Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 60: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032
  • Figure 61: Asia Pacific Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
  • Figure 62: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032
  • Figure 63: Asia Pacific Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032
  • Figure 64: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-032
  • Figure 65: Asia Pacific Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032
  • Figure 66: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032
  • Figure 67: Asia Pacific Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032
  • Figure 68: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032
  • Figure 69: Asia Pacific Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032
  • Figure 70: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032
  • Figure 71: Asia Pacific Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032
  • Figure 72: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 73: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032
  • Figure 74: Latin America Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
  • Figure 75: Latin America Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032
  • Figure 76: Latin America Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032
  • Figure 77: Latin America Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032
  • Figure 78: Latin America Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032
  • Figure 79: Latin America Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032
  • Figure 80: Latin America Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032
  • Figure 81: Latin America Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032
  • Figure 82: Latin America Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032
  • Figure 83: Latin America Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032
  • Figure 84: Latin America Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032
  • Figure 85: Latin America Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 86: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032
  • Figure 87: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
  • Figure 88: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032
  • Figure 89: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032
  • Figure 90: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032
  • Figure 91: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032
  • Figure 92: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032
  • Figure 93: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032
  • Figure 94: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032
  • Figure 95: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032
  • Figure 96: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032
  • Figure 97: Middle East & Africa Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032
  • Figure 98: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032
  • Figure 99: Global Viral Vector Production Market Share, by Company, 2022
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!